Source: http://www.google.es/patents/US7700719
Timestamp: 2013-05-19 13:11:12
Document Index: 321491293

Matched Legal Cases: ['Application No. 05753672', 'Application No. 07747965', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896']

Patente US7700719 - Arctic β amyloid protofibril - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s » B�squeda avanzada de patentes | Historial web | Iniciar sesi�n B�squeda avanzada de patentesPatentesThe present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further...http://www.google.es/patents/US7700719?utm_source=gb-gplus-sharePatente US7700719 - Arctic β amyloid protofibril N�mero de publicaci�nUS7700719 B2Tipo de publicaci�nConcesi�n N�mero de solicitud11/654,508 Fecha de publicaci�n20 Abr 2010 Fecha de presentaci�n18 Ene 2007 Fecha de prioridad7 Jul 2000Tambi�n publicado comoEP1309341A2EP2082749A2EP2082749A3US7179463US20020162129US20120156222WO2002003911A2WO2002003911A3WO2002003911A8WO2002003911B1 InventoresLars LannfeltCamilla NilsberthAnita CampbellJan N�slund Cesionario originalBioarctic Neuroscience Ab Clasificaci�n de EE.UU.530/324424/198.1530/300424/185.1424/184.1 Clasificaci�n internacionalA01K67/027C12N15/09A61K45/00G01N33/15C07K16/18A61K39/395G01N37/00A61P37/04C12N5/10G01N33/50C12N1/15C12N1/21C12N1/19A61P25/28A61K39/38C07K14/47A61K39/00C07K17/00C07K5/00C07K16/00A61K38/00 Clasificaci�n cooperativaC07K14/4711A61K2039/505A61K38/00 Clasificaci�n europeaC07K 14/47A3ReferenciasCitas de patentes (75)Otras citas (260)Enlaces externosUSPTO Cesi�n de USPTO EspacenetArctic β amyloid protofibrilUS 7700719 B2 Resumen The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunisation against AD.
11. The protofibril according to claim 1, wherein said protofibril is a 1:1 mixture of Aβ1-40Arc (Amino Acids 1-40 of SEQ ID NO:1) and Aβ1-40wt (SEQ ID NO:10). Descripci�n
Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS560410227 Oct 199318 Feb 1997Athena Neurosciences, Inc.Methods of screening for β-amyloid peptide production inhibitorsUS56124861 Nov 199318 Mar 1997Athena Neurosciences, Inc.Transgenic animals harboring APP allele having swedish mutationUS56795317 Jun 199521 Oct 1997Bayer CorporationMethods of detecting βA4 peptide species ending at carboxy-terminus residue 42 using monoclonal antibody 369.2BUS57536248 Ago 199619 May 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseaseUS581762614 Mar 19956 Oct 1998Praecis Pharmaceuticals IncorporatedModulators of beta-amyloid peptide aggregationUS585000322 Ene 199715 Dic 1998Athena NeurosciencesTransgenic rodents harboring APP allele having swedish mutationUS585199613 Feb 199822 Dic 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseasesUS585420414 Mar 199629 Dic 1998Praecis Pharmaceuticals, Inc.Aβ peptides that modulate β-amyloid aggregationUS58542157 Jun 199529 Dic 1998Praecis Pharmaceuticals IncorporatedModulators of β-amyloid peptide aggregationUS598524227 Ago 199716 Nov 1999Praecis Pharmaceuticals, Inc.Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS60541147 May 199725 Abr 2000Massachusetts Institute Of TechnologyOrganometallic ligands for the localization and quantification of amyloid in vivo and in vitroUS611413314 Nov 19945 Sep 2000Elan Pharmaceuticals, Inc.Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)US61749168 Ago 199716 Ene 2001Milkhaus Laboratory, Ltd.Methods for treating herpes virus infectionsUS62185065 Feb 199717 Abr 2001Northwestern UniversityAmyloid β protein (globular assembly and uses thereof)US624596410 Dic 199812 Jun 2001Elan Pharmaceuticals, Inc.Transgenic rodent comprising APP-SwedishUS630356727 Ago 199616 Oct 2001Praecis Pharmaceuticals, Inc .Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS631949814 Mar 199620 Nov 2001Praecis Pharmaceuticals IncorporatedModulators of amyloid aggregationUS71794639 Jul 200120 Feb 2007Lars LannfeltTreatment of alzheimer's diseaseUS200201621299 Jul 200131 Oct 2002Avstampet Nr 1666 AbPrevention and treatment of alzheimer's diseaseUS2003006831611 Jun 200210 Abr 2003National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. GovernmentAnti-ADDL antibodies and uses thereofUS2003018701117 Dic 20022 Oct 2003Callaway David J.E.Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based diseaseUS2003023275810 Abr 200318 Dic 2003Hospital For Sick Children And University Of TorontoImmunological methods and compositions for the treatment of Alzheimer's diseaseUS200400491341 Jul 200311 Mar 2004Sliwa John W.System and methods for treatment of alzheimer's and other deposition-related disorders of the brainUS200501240162 Ago 20049 Jun 2005Enh Research InstituteAntibodies specific for toxic amyloid beta protein oligomersUS200600794477 Oct 200513 Abr 2006Wetzel Ronald BStabilized A-beta protofibrillar aggregatesUS2006016627516 May 200527 Jul 2006Northwestern University & University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US200601783026 Abr 200510 Ago 2006Northwestern University & The University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US2006019385027 Ene 200631 Ago 2006Wyeth LlcAnti a beta antibody formulationUS2006022834921 Oct 200512 Oct 2006Merck Sharp & Dohme Corp.Anti-ADDL antibodies and uses thereofUS2006024048615 Dic 200526 Oct 2006Wyeth LlcImmunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesUS2006028073312 Sep 200314 Dic 2006The Regents Of The University Of CaliforniaImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS2007004831231 Jul 20061 Mar 2007National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. GovernmentAnti-ADDL antibodies and uses thereofUS2007008199817 Oct 200612 Abr 2007Merck Sharp & Dohme Corp.Anti-ADDL monoclonal antibody and use thereofUS200700987212 Feb 20043 May 2007Abbott Gmbh & Co. KgAmyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereofUS200700991854 Nov 20033 May 2007Bioarctic Neuroscience AbMethods for the identification of agents that modulate the structure and processing of beta-amyloid precursor proteinUS2007011075013 Sep 200417 May 2007The Regents Of The University Of CaliforniaMonoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS2007014816717 Oct 200628 Jun 2007Merck Sharp & Dohme Corp.Non-immunostimulatory antibody and compositions containing the sameUS2008018190219 Mar 200831 Jul 2008Campbell AnitaPrevention and treatment of alzheimer's diseaseEP0783104A117 Dic 19969 Jul 1997Oriental Yeast Co., Ltd.Method for assaying soluble amyloid precursor proteinWO1991016819A126 Mar 199128 Oct 1991Molecular Rx., Inc.Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta proteinWO1995011994A117 Oct 19944 May 1995Athena Neurosciences, Inc.Methods of screening for beta-amyloid peptide production inhibitorsWO1995031996A125 May 199530 Nov 1995Milkhaus LaboratoryMaterials and methods for treatment of plaquing diseasesWO1997041856A17 May 199713 Nov 1997Brigham And Women'S Hospital, Inc.ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)WO1998033815A15 Feb 19986 Ago 1998Acumen Pharmaceuticals, Inc.Amyloid beta protein (globular assembly and uses thereof)WO1999027944A130 Nov 199810 Jun 1999Athena Neurosciences, Inc.Prevention and treatment of amyloidogenic diseaseWO1999027949A13 Dic 199810 Jun 1999Brigham And Women'S HospitalMETHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASEWO2000039310A129 Dic 19996 Jul 2000Menon, NandaRubredoxin fusion proteins, protein expression system and methodsWO2000071671A226 May 200030 Nov 2000New York UniversityNew mutant genes in familial british dementia and familial danish dementiaWO2000072870A11 Jun 20007 Dic 2000Hirtzer, PamelaCompositions of a-beta peptide and processes for producing sameWO2000072876A21 Jun 20007 Dic 2000Neuralab LimitedPrevention and treatment of amyloidogenic diseaseWO2000072880A226 May 20007 Dic 2000Neuralab LimitedPrevention and treatment of amyloidogenic diseaseWO2001010900A24 Ago 200015 Feb 2001Barlow, AnnGlobular assembly of amyloid beta protein and uses thereofWO2001039796A229 Nov 20007 Jun 2001Chalifour, RobertVaccine for the prevention and treatment of alzheimer's and amyloid related diseasesWO2001090182A222 May 200129 Nov 2001Frangione, BlasSynthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid depositsWO2002003911A25 Jul 200117 Ene 2002Lannfelt, LarsPrevention and treatment of alzheimer's diseaseWO2003089460A17 Abr 200330 Oct 2003The Governing Council Of The University Of TorontoImmunological methods and compositions for the treatment of alzheimer's diseaseWO2003104437A211 Jun 200318 Dic 2003Chang, LeiAnti-addl antibodies and uses thereofWO2004024090A212 Sep 200325 Mar 2004Glabe Charles GImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceWO2004031400A21 Oct 200315 Abr 2004Chang, LeiAmyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereofWO2005019828A120 Ago 20043 Mar 2005Cashman, NeilEpitope protection assay and method for detecting protein conformationsWO2005025516A213 Sep 200424 Mar 2005Glabe, Charles, G.Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregatesWO2005089539A117 Mar 200529 Sep 2005Bioarctic Neuroscience AbTransgenic model for alzheimer�s diseaseWO2005123775A121 Jun 200529 Dic 2005Bioarctic Neuroscience AbAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereofWO2006014478A15 Jul 20059 Feb 2006Chang, LeiMONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)WO2006047254A121 Oct 20054 May 2006Ashe, Karen, H.Assemblies of oligomeric amyloid beta protein and uses thereofWO2006055178A221 Oct 200526 May 2006Acton, PaulAnti-addl antibodies and uses thereofWO2006066233A115 Dic 200522 Jun 2006Jacobson, Jack, StevenAn immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesWO2006083533A217 Ene 200610 Ago 2006Chen, JeannieCompositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disordersWO2006094724A23 Mar 200614 Sep 2006Abbott Gmbh & Co. KgScreening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodiesWO2006137354A119 Jun 200628 Dic 2006Medical & Biological Laboratories Co., Ltd.Antibody having inhibitory effect on amyloid fibril formationWO2007005358A226 Jun 200611 Ene 2007Grimm, Karen, M.Method for preparing a covalently cross linked oligomer of amyloid beta peptidesWO2007005359A126 Jun 200611 Ene 2007Evans, RobertComposition and method for producing stable amyloid beta oligomers of high molecular weightWO2007050359A217 Oct 20063 May 2007An, ZhiqiangAnti-addl monoclonal antibody and use thereofWO2007062088A121 Nov 200631 May 2007Lee, Edward, B.Antibody treatment of alzheimer's and related diseasesWO2007108756A123 Mar 200727 Sep 2007Bioarctic Neuroscience AbImproved protofibril selective antibodies and the use thereofOtras citasReferencia1Advisory Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Feb. 20, 2004.2Andreasen and Blennow, "Beta-amyloid (Abeta) Protein in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease," Peptides 23:1205-1214, 2002.3Axelman et al., "A Large Swedish Family with Alzheimer's Disease with a Codon 670/671 Amyloid Precursor Protein Mutation," Arch. Neurol. 51:1193-1197, 1994.4Bacskai et al., "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," Nature Med. 7(3):369-372, 2001.5Bacskai, et al., Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (Mar. 2001).6Bacskai, et al., Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy, Nature Medicine, 7(3):369-372 (Mar. 2001).7Bard et al., "Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nature Med. 6(8):916-919, 2000.8Bard, et al., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000).9Bard, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, 6(8):916-919 (Aug. 2000).10Barghorn et al., "Globular Amyloid β-Peptide Oligomer: A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease," J. Neurochem. 95:834-47, 2005.11Bayer et al., "Evaluation of the Safety and Immunogenicity of Synthetic Aβ42 (AN1792) in Patients with AD," Neurology 64:94-101, 2005.12Bitan et al., "Amyloid β-Protein (Aβ) Assembly: Aβ40 and Aβ42 Oligomerize Through Distinct Pathways," Proc. Natl. Acad. Sci. U.S.A. 100:330-5, 2003.13Blanchard et al., "Efficient Reversal of Alzheimer's Disease Fibril Formation and Elimination of Neurotoxicity by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 101(40):14326-32, 2004.14Cai et al., "Release of Excess Amyloid β-Protein from a Mutant Amyloid β-Protein Precursor," Science 259:514-516, 1993.15Caughey and Lansbury, "Protofibrils, Pores, Fibils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders," Ann. Rev. Neurosci. 26:267-98, 2003.16Chen et al., "A Learning Deficit Related to Age and β-Amyloid Plaques in a Mouse Model of Alzheimer's Disease," Nature 408:975-978, 2000.17Chen, et al., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000).18Chen, et al., A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease, Nature, 408:975-978 (Dec. 2000).19Chromy et al., "Self-Assembly of Aβ1-42 Into Globular Neurotoxins," Biochemistry 42:12749-12760, 2003.20Chromy et al., "Stability of Small Oligomers of Aβ1-42 (ADDLs)," Society for Neuroscience 25:2129; 852.5, 1999.21Citron et al., "Mutant Presenilins of Alzheimer's Disease Increase Production of 42-Residue Amyloid β-Protein in Both Transfected Cells and Transgenic Mice," Nature Med. 3(1):67-72, 1997.22Citron et al., "Mutation of the (β-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases β-Protein Production," Nature 360:672-674, 1992.23Citron, et al., Mutant presenilins of ALzheinmer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice, Nature Medicin, 3(1) 67-72 (Jan. 1997).24Citron, et al., Mutant presenilins of ALzheinmer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice, Nature Medicin, 3(1) 67-72 (Jan. 1997).25Communication from European Patent Application No. 05753672.4-2402, mailed Jul. 6, 2009.26Conway et al., "Acceleration of Oligomerization, Not Fibrillization, is a Shared Property of Both α-Synuclein Mutations Linked to Early-Onset Parkinson's Disease: Implications for Pathogenesis and Therapy," Proc. Natl. Acad. Sci. U.S.A. 97(2):571-576, 2000.27Conway, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson' disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000).28Conway, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson' disease: Implications for pathogenesis and therapy, PNAS, 97(2):571-576 (Jan. 18, 2000).29Dahlgren et al., "Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability," J. Biol. Chem. 277:32046-53, 2002.30Dalfo et al., "Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease," J. Neuropathol. Exp. Neuro. 64(9):816-830, 2005.31De Jonghe et al., "Flemish and Dutch Mutations in Amyloid β Precursor Protein Have Different Effects on Amyloid β Secretion," Neurobiol. Dis. 5:281-286, 1998.32De Jonghe, et al., Flemish and Dutch Mutations in Amyloid beta Precursor Protein Hane Different Effects on Amyloid beta Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ. Aug. 19, 1998.33De Jonghe, et al., Flemish and Dutch Mutations in Amyloid β Precursor Protein Hane Different Effects on Amyloid β Secretion, Neurobiology of Disease, 5:281-286 (accepted for publ. Aug. 19, 1998.34Declaration Under Rule 132 (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.35DeMarco et al., "From Conversion to Aggregation: Protofibril Formation of the Prion Protein," Proc. Natl. Acad. Sci. U.S.A. 101:2293-2298, 2004.36Dodart et al., "Immunization Reverses Memory Deficits Without Reducing Brain Aβ Burden in Alzheimer's Disease Model," Nature Neurosci. 5:452-457, 2002.37El-Agnaf et al., "Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's Disease," Biochem. Biophys. Res. Comm. 273:1003-1007, 2000.38Enya et al., "Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging," Am. J. Pathol. 154:271-279, 1999.39European Examination Report (EP 01 945 896.7), dated Apr. 24, 2007.40European Examination Report (EP 01 945 896.7), dated May 22, 2006.41European Examination Report (EP 01 945 896.7), dated Sep. 30, 2005.42Extended European Search Report from European Patent Application No. 07747965.7, dated May 13, 2009.43Finder and Glockshuber, "Amyloid-β Aggregation," Neurodegener. Dis. 4(1):13-27, 2007.44Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala ->Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.45Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala →Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.46Forsell, et al., Amyloid precursor protein mutation at codon 713(Ala-Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent) , Newroscience Letters, 184:90-93 (accepted Nov. 18, 1994).47Frackowiak et al., "Non-Fibrillar β-Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease," J. Neuropathol. Exp. Neurol. 53:637-645, 1994.48Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," J. Neuroimmunol. 106:23-31, 2000.49Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," Neuroimmunomodulation 6:444, 1999.50Frenkel et al., "Immunization Against Alzheimer's β-Amyloid Plaques Via EFRH Phage Administration," Proc. Natl. Acad. Sci. U.S.A. 97(21):11455-11459, 2000.51Frenkel, et al., Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000).52Frenkel, et al., Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration, PNAS, 97(21):11455-11459 (Oct. 10, 2000).53Giulian et al., "The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," J. Biol. Chem. 273(45):29719-29726, 1998.54Giulian, et al., The HHQK Domain of beta-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998).55Giulian, et al., The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease, The Journal of Biological Chemistry, 273(45):29719-29726 (Nov. 6, 1998).56Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochem. Biophys. Res. Comm. 120(3):885-890, 1984.57Grabowski et al., "Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy," Ann. Neuro. 49:697-705, 2001.58Grabowski, et al., Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy, Ann. Neurol., 49:697-705 (published online Mar. 19, 2001).59Guerette et al., "Oligomeric Aβ in PBS-Soluble Extracts of Human Alzheimer Brain," Society for Neuroscience 25:2129; 852.1, 1999.60Hardy, "Amyloid, the Presenilins and Alzheimer's Disease," Trends Neurosci. 20(4):154-159, 1997.61Hardy, "Framing β-Amyloid," Nature Genet. 1:233-234, 1992.62Hardy, Amyloid, the presenillins and Alzheimer's disease, Trends Neurosci., 20(4):154-159 (1997).63Harper et al., "Assembly of Aβ Amyloid Protofibrils: An In Vitro Model for a Possible Early Event in Alzheimer's Disease," Biochemistry 38:8972-8980, 1999.64Harper et al., "Observation of Metastable Aβ Amyloid Protofibrils by Atomic Force Microscopy," Chem. Biol. 4:119-125, 1997.65Harper, et al., Assembly of Abeta Amyloid Protofibrils: An in Vitro Model for aPossible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online Jun. 18, 1999).66Harper, et al., Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for aPossible Early Event in Alzheimer's Disease, Biochemistry, 38:8972-8980 (published online Jun. 18, 1999).67Hartley et al., "Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons," J. Neurosci. 19(20):8876-8884, 1999.68Hendriks et al., "Presenile Dementia and Cerebral Hemorrhage Linked to a Mutation at Codon 692 of the β- Amyloid Precursor Protein Gene," Nature Genet. 1:218-221, 1992.69Hendriks, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene, Nature Genetics, 1:218-221 (Jun. 1992).70Hendriks, et al., Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene, Nature Genetics, 1:218-221 (Jun. 1992).71Hock and Nitsch, "Clinical Observations with AN-1792 Using TAPIR Analyses," Neurodegener Dis. 2:273-276, 2005.72Hoshi et al., "Spherical Aggregates of β-Amyloid (Amylospheroid) Show High Neurotoxicity and Activate Tau Protein Kinase I/glycogen Synthase Kinase-3β," Proc. Natl. Acad. Sci. U.S.A. 100(11):6370-6375, 2003.73International Preliminary Report (PCT/US2003/30930), completed Feb. 6, 2006.74International Preliminary Report on Patentability (PCT/SE01/01553), completed Oct. 23, 2002.75International Preliminary Report on Patentability (PCT/SE05/000993), issued Dec. 28, 2006.76International Preliminary Report on Patentability (PCT/SE07/000292), issued Sep. 23, 2008.77International Preliminary Report on Patentability (PCT/US2003/19640), completed Aug. 7, 2006.78International Search Report (PCT/SE01/01553), mailed Feb. 4, 2002.79International Search Report (PCT/SE05/000993), mailed Oct. 4, 2005.80International Search Report (PCT/SE07/000292), mailed Jul. 20, 2007.81Interview Summary (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), dated Oct. 21, 2003.82Isaacs et al., "Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium," J. Biol. Chem. 281(38):27916-23, 2006.83Janus et al., "A β Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," Nature 408:979-982, 2000.84Janus, et al., Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000).85Janus, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408:979-982 (Dec. 2000).86Jensen et al., "Quantification of Alzheimer Amyloid beta Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.87Jensen et al., "Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.88Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Abeta1-42 Arctic and Abeta1-42 wt" FEBS J. 273:2618-2630, 2006.89Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Aβ1-42 Arctic and Aβ1-42 wt" FEBS J. 273:2618-2630, 2006.90Johnston et al., "Increased beta-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.91Johnston et al., "Increased β-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.92Kamino et al., "Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Region," Am. J. Hum. Genet. 51:998-1014, 1992.93Kamino, et al., Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Regin, Am. J. Hum. Genet. 51:998-1014 (revision reveived Jul. 24, 1992.94Kang et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-surface Receptor," Nature 325:733-736, 1987.95Kayed et al., "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis," Science 300:486-489, 2003.96Kayed et al., "Immunization With a Molecular Mimic of a Toxic Aggregates Generates a Conformation-Dependent Antibody Specific for High Molecular Weight A Aggregates (Micelles and Protofibrils)," 32nd Annual Meeting of the Society for Neuroscience, Orlando, Florida (Society for Neuroscience Abstract Viewer and Itinerary Planner, Abstract No. 685.3, 2002).97Kirkitadze et al., "Paradigm Shifts in Alzheimer's Disease and Other Neurodegenerative Disorders:The Emerging Role of Oligomeric Assemblies," J. Neurosci. Res. 1, 69:567-77, 2002.98Klafki et al., "Therapeutic Approaches to Alzheimer's Disease," Brain 129:2840-2855, 2006.99Klein et al., "Oligemia-Induced Expression of c-fos and Oxidative Stress-Related Protein in the Murine Brain," 30th Annual Meeting of the Society of Neuroscience, New Orleans, LA, Nov. 4-9, 2000, Soc. Neurosci. Abstracts 26(1-2), Abstract 383.15, 2000.100Klein et al., "Oligomer/Conformation-Dependent Aβ Antibodies," Soc. Neurosci. Abstr. Presentation No. 475.11, Tuesday Nov. 7, 2000.101Klein et al., "Targeting Small Aβ Oligomers: The Solution to an Alzheimer's Disease Conundrum?" Trends Neurosci. 24:219-224, 2001.102Klein, "Aβ Toxicity in Alzheimer's Disease," Contemporary Clinical Neuroscience: Molecular Mechanisms of Neurodegenerative Diseases 1.1 Introduction, 2001.103Klyubin et al., "Inhibitory Effect of Amyloid-β Peptide with the Arctic Mutation on Long-term Potentiation in Area CA1 of Rat Hippocampus In Vivo," J. Physio., 551P, C32, 2003.104Klyubin et al., "Soluble Arctic Amyloid β Protein Inhibits Hippocampal Long-Term Potentiation In Vivo," Eur. J. Neurosci. 19:2839-2846, 2004.105Kuo et al., "Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," J. Biol. Chem. 271:4077-4081, 1996.106Lambert et al., "Diffusible, Nonfibrillar Ligands Derived From Aβ1-42 Are Potent Central Nervous System Neurotoxins," Proc. Natl. Acad. Sci. U.S.A. 95:6448-6453, 1998.107Lambert et al., "Monoclonal Antibodies that Target Pathological Assemblies of Aβ," J. Neurochem. 100:23-35, 2007.108Lambert et al., "Neuron Dysfunction and Death Caused by Small Aβ Oligomers: Role of Signal Transduction," Society for Neuroscience 25:2129, 1999.109Lambert et al., "Vaccination With Soluble Aβ Oligomers Generates Toxicity-Neutralizing Antibodies," J. Neurochem. 79:595-605, 2001.110Lannfelt et al., "Amyloid beta-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.111Lannfelt et al., "Amyloid Precursor Protein Mutation Causes Alzheimer's Disease in a Swedish Family," Neurosci. Lett. 168:254-256, 1994.112Lannfelt et al., "Genetics of Alzheimer's Disease-Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.113Lannfelt et al., "Genetics, Pathophysiology and Abeta Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.114Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Abeta Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.115Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.116Lannfelt et al., "Amyloid β-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.117Lannfelt et al., "Genetics of Alzheimer's Disease�Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.118Lannfelt et al., "Genetics, Pathophysiology and Aβ Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.119Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Aβ Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.120Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.121Lashuel et al., "Mixtures of Wild-Type and a Pathogenic (E22G) Form of Aβ40 In Vitro Accumulate Protofibrils, Including Amyloid Pores," J. Mol. Biol. 332:795-808, 2003.122Lee et al., "Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice," J. Biol. Chem. 2006 281:4292-4299.123Levy et al., "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type," Science 248:1124-1126, 1990.124Levy, et al., Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type, Science, 248:1124-1126 (Jun. 1, 1990).125Liu et al., "Residues 17-20 and 30-35 of β-Amyloid Play Critical Roles in Aggregation," J. Neurosci. Res. 75(2):162-71, 2004.126Longo and Finch, "Nonfibrillar Aβ 1-42 (ADDL) Causes Aconitase Inactivation and Iron-dependent Neurotoxicity," Society for Neuroscience 25: 2129, 1999.127Masters et al., "Amyloid Plaque Core Protein in Alzheimer's Disease and Down Syndrome," Proc. Natl. Acad. Sci. U.S.A. 82:4245-4249, 1985.128McKhann et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCHS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology 34:939-944, 1994.129Minutes from Oral Proceedings for European Patent Application No. 01945896.7-2402, dated Dec. 17, 2008.130Miravelle et al., "Substitutions at Codon 22 of Alzheimer's Aβ Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells," J. Biol. Chem. 275:27110-27116, 2000.131Morgan et al., "Aβ Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," Nature 408:982-985, 2000.132Morgan, et al., Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000).133Morgan, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408:982-985 (Dec. 2000).134Moss et al., "The Peptide KLVFF-K6 Promotes β-Amyloid(1-40) Protofibril Growth by Association but Does Not Alter Protofibril Effects on Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)," Mol . Pharmacol. 64(5):1160-8, 2003.135Motter et al., "Reduction of β-Amyloid Peptide42 in the Cerebrospinal Fluid of Patients with Alzheimer's Disease," Ann. Neurol. 38:643-648, 1995.136Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of beta-Amyloid," Nature Genet. 1:345-347, 1992.137Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of β-Amyloid," Nature Genet. 1:345-347, 1992.138Mullan, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid, Natue Genetics, 1:345-347 (Aug. 1992).139Mullan, et al., A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid, Natue Genetics, 1:345-347 (Aug. 1992).140Nichols et al., "Amyloid-β Aggregates Formed at Polar-Nonpolar Interfaces Differ From Amyloid-β Protofibrils Produced in Aqueous Buffers," Microsc. Res. Tech. 67(3-4):164-74, 2005.141Nicoll et al., "Neuropathology of Human Alzheimer Disease After Immunization With Amyloid-β Peptide: A Case Report," Nature Med. 9(4):448-452, 2003.142Nilsberth et al., "A Novel APP Mutation (E693G)-The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.143Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.144Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.145Nilsberth et al., "The Artic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid beta Protofibril Formation and Decreased Amyloid beta Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.146Nilsberth et al., "A Novel APP Mutation (E693G)�The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.147Nilsberth et al., "The �Arctic� APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.148Nilsberth et al., "The �Arctic� APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.149Nilsberth et al., "The Artic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid β Protofibril Formation and Decreased Amyloid β Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.150Notice of Allowance (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Oct. 16, 2006.151Notice of Appeal (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Nov. 25, 2003.152Notice of intent to grant a European patent and Annex (Reasons for Decision) (EP 01 945 896.7), dated Mar. 18, 2009.153Notice of Non-Compliant Amendment (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed May 12, 2005.154Oda et al., "Clusterin (apoJ) Alters the Aggregation of Amyloidβ-Peptide (Aβ 1-42) and Forms Slowly Sedimenting Aβ Complexes that Cause Oxidative Stress," Exp. Neurol. 136:22-31, 1995.155Oda et al., "Purification and Characterization of Brain Clusterin," Biochem. Biophys. Res. Comm. 204:1131-6, 1994.156Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463) mailed May 8, 2006.157Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 7, 2005.158Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 25, 2003.159Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 19, 2002.160Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 24, 2004.161Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 9, 2005.162O'Nuallain et al., "Conformational Abs Recognizes a Generic Amyloid Fibril Epitope," Proc. Natl. Acad. Sci. U.S.A. 99:1485-1490, 2002.163P�ivi� et al., "Unique Physicochemical Profile of beta-Amyloid Peptide Variant Abeta 1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.164P�ivi� et al., "Unique Physicochemical Profile of β-Amyloid Peptide Variant Aβ 1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.165Palmert et al., "The β-Amyloid Protein Precursor of Alzheimer Disease Has Soluble Derivatives Found in Human Brain and Cerebrospinal Fluid," Proc. Natl. Acad. Sci. U.S.A. 86:6338-6342, 1989.166Palmert, et al., The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989).167Palmert, et al., The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci. USA, 86:6338-6342 (Aug. 1989).168Pirttil� et al., "Soluble Amyloid β-Protein in the Cerebrospinal Fluid From Patients with Alzheimer's Disease, Vascular Dementia and Controls," J. Neurol. Sc. 127:90-95, 1994.169Ponte et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," Nature 331:525-527, 1988.170Qin et al., "Effect of 4-Hydroxy-2-Nonenal Modification on Alpha-Synuclein Aggregation," J. Biol. Chem. 282(8):5862-5870, 2007.171Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Apr. 7, 2006.172Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Nov. 5, 2007.173Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Sep. 22, 2006.174Reply to Notice of Non-Compliant Amendment (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed May 27, 2005.175Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Apr. 21, 2003.176Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Aug. 8, 2006.177Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Dec. 18, 2003.178Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 24, 2005.179Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.180Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Oct. 7, 2005.181Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 10, 2004.182Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 3, 2002.183Request For Continued Examination (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 25, 2004.184Request Pursuant to Oral Proceedings (European Patent Application No. 01945896.7-2402), mailed Oct. 10, 2008.185Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 3, 2002.186Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 10, 2004.187Resubmission of Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Feb. 3, 2004.188Roher et al., "Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease," J. Biol. Chem. 271:20631-20635, 1996.189Russo et al., "Presenilin-1 Mutations in Alzheimer's Disease," Nature 405:531-532, 2000.190Rzepecki et al., "Prevention of Alzheimer's Disease-Associated Aβ Aggregation by Rationally Designed Nonpeptitdic β-Sheet Ligands," J. Biol. Chem. 279:47497-47505, 2004.191Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-beta Production by Making Amyloid Precursor Protein Less Available to alpha -secretase," J. Neurochem. 101:854-862, 2007.192Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-β Production by Making Amyloid Precursor Protein Less Available to α -secretase," J. Neurochem. 101:854-862, 2007.193Schenk et al., "Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP," Nature 400:173-177, 1999.194Schenk, et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (Jul. 8, 1999).195Schenk, et al., Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP, Letters to Nature, 400:173-177 (Jul. 8, 1999).196Scheuner et al., "Secreted Amyloid beta-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease." Nature Med. 2(8):864-870, 1996.197Scheuner et al., "Secreted Amyloid β-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease." Nature Med. 2(8):864-870, 1996.198Scheuner, et al., Secreted amyloid beta-protein similar to that in thesenile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996).199Scheuner, et al., Secreted amyloid β-protein similar to that in thesenile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 2(8):864-870 (Aug. 1996).200Selkoe, "Cell Biology of the Amyloid β-Protein Precursor and the Mechanism of Alzheimer's Disease," Ann. Rev. Cell Biol. 10:373-403, 1994.201Selkoe, "Normal and Abnormal Biology of the β-Amyloid Precursor Protein," Ann. Rev. Neurosci. 17:489-517, 1994.202Serpell, "Alzheimer's Amyloid Fibrils: Structure and Assembly," Biochim. Biophys. Acta 1502:16-30, 2000.203Serpell, Alzheimer's amyloid fibrils: structure and assembly, Biochimica et Biophysica Acta, 1502:16-30 (accepted Nov. 24, 1999).204Seubert et al., "Isolation and Quantification of Soluble Alzheimer's β-Peptide From Biological Fluids," Nature 359:325-327, 1992.205Sherrington et al., "Cloning of a Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease," Nature 375:754-760, 1995.206Sherrington et al., Cloning of agene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375:754-760 (Jun. 29, 1995).207Shtilerman et al., "Molecular Crowding Accelerates Fibrillization of α-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease?" Biochemistry 41:3855-3860, 2002.208Sigurdsson et al., "Immunization With a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," Am. J. Pathol. 159(2):439-447, 2001.209Solomon et al., "Disaggregation of Alzheimer β-amyloid by Site-directed mAb," Proc. Natl. Acad. Sci. U.S.A. 94:4109-4112, 1997.210Solomon et al., "Monoclonal Antibodies Inhibit In Vitro Fibrillar Aggregation of the Alzheimer Beta-amyloid Peptide," Proc. Natl. Acad. Sci. U.S.A. 93:452-455, 1996.211Solomon et al., "Monoclonal Antibodies Restore and Maintain the Soluble Conformation of β-amyloid Peptide," Neurobiol. Aging, vol. 17, No. 4, Suppl. 152, 1996.212Soto et al., "The Conformation of Alzheimer's β Peptide Determines the Rate of Amyloid Formation and Its Resistance to Proteolysis," Biochem. J. 1:314:701-7, 1996.213Srinivasan et al., "ABri Peptide Associated with Familial British Dementia Forms Annular and Ring-Like Protofibrillar Structures," Amyloid 11(1):10-3, 2004.214St. George-Hyslop et al., "Genetic Linkage Studies Suggest that Alzheimer's Disease is Not a Single Homogeneous Disorder," Nature 347:194-197, 1990.215St. George-Hyslop et al., "The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21," Science 235:885-890, 1987.216St. George-Hyslop, et al., Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder, Letters to Nature, 347:194-197 (Sep. 13, 1990).217St. George-Hyslop, et al., The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21, Science, 235:885-890( Feb. 20, 1987).218Stenh et al., "Amyloid-beta Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.219Stenh et al., "The Arctic Mutation Interferes with Processing of the Amyloid Precursor Protein," NeuroReport 13: 1857, 2002.220Stenh et al., "Amyloid-β Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.221Stine et al., "Supramolecular Structures of Aβ Aggregates and Cellular Responses," Biophysical Journal Program and Abstracts:40th Annual Meeting Feb. 17-21, 1996, Biophys J. 70: Abstract 239.222Stine et al., "The Nanometer-Scale Structure of Amyloid-β Visualized by Atomic Force Microscopy," J. Prot. Chem. 15(2):193-203, 1996.223Summons to Attend Oral Proceedings (European Patent Application No. 01945896.7-2402), dated Jul. 25, 2008.224Supplemental Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 21, 2004.225Suzuki et al., "An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants," Science 264:1336-1340, 1994.226Suzuki, et al., An Increase Percentage of Long Amyloid beta Protein Secreted by Familial Amyloid beta Protein Precursor (betaAPP717) Mutants, Science, 264:1336-1340 (May 27, 1994).227Suzuki, et al., An Increase Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants, Science, 264:1336-1340 (May 27, 1994).228Tagliavani et al., "A New βAPP Mutation Related to Hereditary Cerebral Haemorrhage," Alz. Report 2(Suppl. 1):S28, Abstract 23, 1999.229U.S. Appl. No. 09/369,236, filed Aug. 4, 1999, Krafft et al.230U.S. Appl. No. 09/745,057, filed Dec. 20, 2000, Krafft et al.231U.S. Appl. No. 10/166,856, filed Jun. 11, 2002, Klein et al.232U.S. Appl. No. 11/570,995, filed Dec. 20, 2006, Gellerfors et al.233U.S. Appl. No. 12/294,207, filed Sep. 23, 2008, Gellerfors et al.234U.S. Appl. No. 60/217,098, filed Jul. 10, 2000, Lannfelt et al.235U.S. Appl. No. 60/621,776, filed Oct. 25, 2004, Lambert et al.236U.S. Appl. No. 60/652,538, filed Feb. 14, 2005, Shughrue et al.237Vickers, "A Vaccine Against Alzheimer's Disease: Developments to Date," Drugs Aging 19(7):487-494, 2002.238Vickers, 2002, Drugs Aging, 19(7), pp. 487-494.239Walsh et al., "Amyloid β-Protein Fibrillogenesis. Detection of a Protofibrillar Intermediate," J. Biol. Chem. 272:22364-22372, 1997.240Walsh et al., "Amyloid β-Protein Fibrillogenesis. Structure and Biological Activity of Protofibrillar Intermediates," J. Biol. Chem. 274(35):25945-25952, 1999.241Walsh et al., "Amyloid-β Oligomers: Their Production, Toxicity and Therapeutic Inhibition," Biochem. Soc. Trans. 30:552-7, 2002.242Walsh et al., "Naturally Secreted Oligomers of Amyloid β Protein Potently Inhibit Hippocampal Long-Term Potentiation In Vivo," Nature 416:535-539, 2002.243Walsh et al., "Oligomers on the Brain: The Emerging Role of Soluble Protein Aggregates in Neurodegeneration," Protein Pept. Lett., 11: 213-28, 2004.244Walsh, et al., Amyloid beta-Protein Fibrillogenesis, the Journal of Biological Chemistry, 272(35):22364-22372 (Aug. 29, 1997).245Walsh, et al., Amyloid β-Protein Fibrillogenesis, the Journal of Biological Chemistry, 272(35):22364-22372 (Aug. 29, 1997).246Ward et al., "Fractionation and Characterization of Oligomeric, Protofibrillar Forms of β-Amyloid Peptide," Biochem. J. 348:137-144, 2000.247Weidemann et al., "Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein," Cell 57:115-126, 1989.248Weidemann, et al., Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein, Cell 57:115-126 (Apr. 7, 1989).249Weiner et al., "Nasal Administration of Amyloid-β Peptide Decreases Cerebral Amyloid Burden in a Mouse Model of Alzheimer's Disease," Annals Neurol. 48(4):567-579, 2000.250Westlind-Danielsson and Arnerup, "Spontaneous In Vitro Formation of Supramolecular β-Amyloid Structures, "βamy Balls", by β-Amyloid 1-40 peptide," Biochemistry 40:14736-43, 2001.251Williams et al., "Structural Properties of Aβ Protofibrils Stabilized by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 102(20):7115-20, 2005.252Wirak et al., "Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice," Science 253:323-325, 1991.253Wirak, et al., Deposits of Amyloid beta Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (Jul. 19, 1991).254Wirak, et al., Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice, Science, 253:323-325 (Jul. 19, 1991).255WO 05/123775 A1, pp. 7-8, published Dec. 29, 2005.256Written Opinion of the International Searching Authority (PCT/SE05/000993), mailed Oct. 4, 2005.257Written Opinion of the International Searching Authority (PCT/SE07/000292), mailed Jul. 20, 2007.258Ye et al., "Protofibrils of Amyloid β-Protein Inhibit Specific K+ Currents in Neocortical Cultures," Neurobiol. Dis. 13:177-190, 2003.259Yoritaka et al., "Immunohistochemical Detection of 4-Hydroxynonenal Protein Adducts in Parkinson Disease," Proc. Natl. Acad. Sci. U.S.A. 93:2696-2701, 1996.260Yoshikai et al., "Genomic Organization of the Human Amyloid Beta-protein Precursor Gene," Gene 87:257-263, 1990.GirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Danos tu opini�nDatos proporcionados por IFI CLAIMS Patent Services©2012 Google